According to a study by Jiang et al. [50], concomitant treatment with LYC at a dose of 20 mg/kg significantly lowered blood levels of AST and ALT in a rat model of NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.